Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis

@article{Stich2016PrevalenceON,
  title={Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis},
  author={Oliver Stich and S A Perera and Benjamin Berger and Sven Jarius and Brigitte Wildemann and A. Baumgartner and Sebastian Rauer},
  journal={Journal of the Neurological Sciences},
  year={2016},
  volume={364},
  pages={29-32}
}

Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

TLDR
It is confirmed that antibodies targeting the Flotillin 1/2 complex are present in a subgroup of patients with MS, and further studies are needed to understand the clinical and pathological relevance of anti-FLOT1/2 autoantibodies in MS.

From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases

TLDR
It is worth noting that quite a few patients show CNS-impaired signs only, and cranial MRI is essential for the screening of CNS involvement, and CSF white blood cell counts were found significantly elevated in CNS-involved patients compared with patients of PNS group.

Anti-neurofascin autoantibody and demyelination

Anti-Neurofascin Antibodies Associated with White Matter Diseases of the Central Nervous System: A Red Flag or a Red Herring?

TLDR
Larger studies are needed to assess the relevance of ANFAs in demyelinating nervous system diseases, their impact on long-term clinical outcomes, and associated therapeutic implications.

Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy.

TLDR
The discovery of autoantibodies against nodal and paranodal proteins has proven useful in clinical practice, has uncovered novel pathophysiological mechanisms, clinical phenotypes, therapeutic response and prognosis within the CIDP disease spectrum and has boosted the search for other clinically relevant autoantIBodies.

Role of B cells and antibodies in multiple sclerosis.

Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies

TLDR
Preliminary evidence suggests that GBS/CIDP patients without detectable IgG antibodies on routine diagnostic tests may nevertheless benefit from IA, and that an unbiased screening approach using myelinating co-cultures may assist in the detection of further autoantibodies which remain to be identified in such patients.

Focal loss of the paranodal domain protein Neurofascin155 in the internal capsule impairs cortically induced muscle activity in vivo

Paranodal axoglial junctions are essential for rapid nerve conduction and the organization of axonal domains in myelinated axons. Neurofascin155 (Nfasc155) is a glial cell adhesion molecule that is

Nodes of Ranvier during development and repair in the CNS

TLDR
The organization and function of CNS nodes of Ranvier are described and how these nodes change in demyelination and remyelinating disorders is considered, highlighting the impact of these changes on neuronal physiology in health and disease as well as the associated therapeutic implications.

References

SHOWING 1-10 OF 27 REFERENCES

Neurofascin as a target for autoantibodies in peripheral neuropathies

TLDR
Autoantibodies to NF are detected in a very small proportion of patients with AIDP and patients with CIDP, but may nevertheless be pathogenic in these cases.

Anti-neurofascin antibody in patients with combined central and peripheral demyelination

TLDR
In anti-neurofascin antibody–positive CCPD patients, including those with a limited response to corticosteroids, IV immunoglobulin or plasma exchange alleviated the symptoms, recognition of this antibody may be important, because patients with CCPD who are antibody positive respond well to IV immunglobulinor plasma exchange.

Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg

TLDR
This study provides Class IV evidence that autoantibodies to NF155 identify a CIDP subtype characterized by severe neuropathy, poor response to IVIg, and disabling tremor.

Neurofascin as a novel target for autoantibody-mediated axonal injury

TLDR
A novel mechanism of immune-mediated axonal injury that can contribute to axonal pathology in MS is identified and identified through a proteomics-based approach.

Autoantibodies in neuroimmunological diseases; relevance of fine specificity

Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis.

TLDR
The elevated presence of anti-MOG antibody is not specific for MS because a similar appearance was also demonstrated in patients with ONDs, and it is not clear whether this antibody is pathogenic in MS or, on the contrary, has a defensive role against further immune-mediated damage after myelin breakdown.

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

TLDR
Data support an immunopathogenetic mechanism whereby B-cell follicles developing in the multiple sclerosis meninges exacerbate the detrimental effects of humoral immunity with a subsequent major impact on the integrity of the cortical structures.

Humoral autoimmunity in multiple sclerosis

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance

TLDR
AQP4-Ab are detectable in the CSF of most patients with NMOSD, mainly during relapse, and are highly specific for this condition, according to the unique localisation of the target antigen at the blood brain barrier.